TY - JOUR
T1 - Trends in Targeted Therapy Usage in Inflammatory Bowel Disease :
T2 - TRENDY Study of ENEIDA
AU - Gómez-Labrador, C.
AU - Ricart, Elena
AU - Iborra, Marisa
AU - Iglesias, E.
AU - Martín-Arranz, M.D.
AU - de Castro, L.
AU - De Francisco, R.
AU - García-Alonso, F.J.
AU - Sanahuja, A.
AU - Gargallo-Puyuelo, C.J.
AU - Mesonero, F.
AU - Casanova, M.J.
AU - Mañosa i Ciria, Míriam
AU - Rivero, Montserrat
AU - Calvo, M.
AU - Sierra Ausín, Mónica
AU - González-Muñoza, C.
AU - Calvet Calvo, Xavier
AU - Hospital Universitario Miguel Servet, null
AU - Guardiola, Jordi
AU - Arias García, L.
AU - Márquez-Mosquera, Lucía
AU - Gutiérrez Casbas, Ana
AU - Zabana, Yamile
AU - Navarro-Llavat, Mercè
AU - Lorente Poyatos, R.
AU - Piqueras, M.
AU - Torrealba, L.
AU - Bermejo, F.
AU - Ponferrada-Díaz, Á.
AU - Pérez-Calle, J.L.
AU - Barreiro de-Acosta, Manuel
AU - Tejido, C.
AU - Cabriada, José Luis
AU - Marín-Jiménez, I.
AU - Roncero, Ó.
AU - Ber, Y.
AU - Fernández-Salazar, L.
AU - Camps Aler, B.
AU - Lucendo, Alfredo J
AU - Llaó, J.
AU - Bujanda, L.
AU - Muñoz Villafranca, C.
AU - Domènech, Eugeni
AU - Chaparro, María
AU - P. Gisbert, Javier
PY - 2024/5
Y1 - 2024/5
N2 - Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.
AB - Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.
KW - Biologics
KW - Biosimilars
KW - Crohn's disease
KW - Inflammatory bowel disease
KW - Positioning
KW - Targeted therapy
KW - Trends
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85194234978&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/ea59f8d7-1471-31aa-9fe9-8c8897bdb0dd/
U2 - 10.3390/pharmaceutics16050629
DO - 10.3390/pharmaceutics16050629
M3 - Article
C2 - 38794292
SN - 1999-4923
VL - 16
JO - Pharmaceutics
JF - Pharmaceutics
IS - 5
M1 - 629
ER -